Pathophysiologically based treatment interventions in schizophrenia

Nature Medicine

Volumn 12, Issue 9, 2006, Pages 1016-1022

  Lewis, David A ^a   Gonzalez Burgos, Guillermo ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; DOPAMINE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID;

CLINICAL FEATURE; COGNITIVE DEFECT; COMORBIDITY; HUMAN; IMMUNOREACTIVITY; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; WORKING MEMORY;

DOPAMINE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HUMANS; MEMORY DISORDERS; MODELS, NEUROLOGICAL; PREFRONTAL CORTEX; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 33748474553     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1478     Document Type: Review

References (107)

1. Hyman, S.E. & Fenton, W.S. Medicine. What are the right targets for psychopharmacology? Science 299, 350-351 (2003).
2. Lieberman, J.A. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209-1223 (2005).
3. Insel, T.R. & Scolnick, E.M. Cure therapeutics and strategic prevention: raising the bar for mental health research. Mol. Psychiatry 11, 11-17 (2006).
4. Harrison, P.J. & Weinberger, D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 10, 40-68 (2005).
5. Lewis, D.A. & Levitt, P. Schizophrenia as a disorder of neurodevelopment. Annu. Rev. Neurosci. 25, 409-432 (2002).
6. Lewis, D.A., Hashimoto, T. & Volk, D.W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 6, 312-324 (2005).
7. Mirnics, K., Levitt, P. & Lewis, D.A. Critical appraisal of DNA microarrays in psychiatric genomics. Biol. Psychiatry 60, 163-176 (2006).
8. Lewis, D.A. The human brain revisited: Opportunities and challenges in postmortem studies of psychiatric disorders. Neuropsychopharmacology 26, 143-154 (2002).
9. Elvevag, B. & Goldberg, T.E. Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol. 14, 1-21 (2000).
10. Gold, J.M. Cognitive deficits as treatment targets in schizophrenia. Schizophr. Res. 72, 21-28 (2004).
11. Keefe, R.S., Eesley, C.E. & Poe, M.P. Defining a cognitive function decrement in schizophrenia. Biol. Psychiatry 57, 688-691 (2005).
12. Green, M.F. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 153, 321-330 (1996).
13. Baddeley, A. Working memory. Science 255, 556-559 (1992).
14. Barch, D.M. What can research on schizophrenia tell us about the cognitive neuroscience of working memory? Neuroscience 139, 73-84 (2006).
15. Tan, H.Y., Choo, W.C., Fones, C.S. & Chee, M.W. fMRI study of maintenance and manipulation processes within working memory in first-episode schizophrenia. Am. J. Psychiatry 162, 1849-1858 (2005).
16. Cannon, T.D. et al. Dorsolateral prefrontal cortex activity during maintenance and manipulation of information in working memory in patients with schizophrenia. Arch. Gen. Psychiatry 62, 1071-1080 (2005).
17. Callicott, J.H. et al. Complexity of prefrontal cortical dysfunction in schizophrenia: More than up or down. Am. J. Psychiatry 160, 2209-2215 (2003).
18. MacDonald, A.W., III et al. Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in never-medicated patients with first-episode psychosis. Am. J. Psychiatry 162, 475-484 (2005).
19. Barch, D.M., Sheline, Y.I., Csernansky, J.G. & Snyder, A.Z. Working memory and prefrontal cortex dysfunction: Specificity to schizophrenia compared with major depression. Biol. Psychiatry 53, 376-384 (2003).
20. Olney, J.W. & Farber, N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52, 998-1007 (1995).
21. Moghaddam, B. Bringing order to the glutamate chaos in schizophrenia. Neuron 40, 881-884 (2003).
22. Coyle, J.T. The GABA-glutamate connection in schizophrenia: which is the proximate cause? Biochem. Pharmacol. 68, 1507-1514 (2004).
23. Krystal, J.H. et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199-214 (1994).
24. Adler, C.M. et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am. J. Psychiatry 156, 1646-1649 (1999).
25. Verma, A. & Moghaddam, B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J. Neurosci. 16, 373-379 (1996).
26. Dudkin, K.N., Kruchinin, V.K. & Chueva, I.V. Neurophysiological correlates of delayed visual differentiation tasks in monkeys: the effects of the site of intracortical blockade of NMDA receptors. Neurosci. Behav. Physiol. 31, 207-218 (2001).
27. Wang, X.J. Toward a prefrontal microcircuit model for cognitive deficits in schizophrenia. Pharmacopsychiatry 39 Suppl 1, S80-S87 (2006).
28. Durstewitz, D. & Seamans, J.K. Beyond bistability: biophysics and temporal dynamics of working memory. Neuroscience 139, 119-133 (2006).
29. Goldman-Rakic, P.S. Cellular basis of working memory. Neuron 14, 477-485 (1995).
30. Scherzer, C.R. et al. Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: hippocampus and cortex. J. Comp. Neurol. 390, 75-90 (1998).
31. Konradi, C. & Heckers, S. Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol. Ther. 97, 153-179 (2003).
32. Kristiansen, L.V., Beneyto, M., Haroutunian, V. & Meador-Woodruff, J.H. Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Mol. Psychiatry 11, 737-747 (2006).
33. Akbarian, S. et al. Selective alterations in gene expression of NMDA receptor subunits in prefrontal cortex of schizophrenics. J. Neurosci. 16, 19-30 (1996).
34. Dracheva, S. et al. N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am. J. Psychiatry 158, 1400-1410 (2001).
35. Mirnics, K., Middleton, F.A., Marquez, A., Lewis, D.A. & Levitt, P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28, 53-67 (2000).
36. Tsai, G. et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry 52, 829-836 (1995).
37. Hakak, Y. et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl. Acad. Sci. USA 98, 4746-4751 (2001).
38. Stefansson, H. et al. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71, 877-892 (2002).
39. Munafo, M.R., Thiselton, D.L., Clark, T.G. & Flint, J. Association of the NRG1 gene and schizophrenia: a meta-analysis. Mol. Psychiatry 11, 539-546 (2006).
40. Tosato, S., Dazzan, P. & Collier, D. Association between the neuregulin 1 gene and schizophrenia: a systematic review. Schizophr. Bull. 31, 613-617 (2005).
41. Hahn, C.G. et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA〉 receptor hypofunction in schizophrenia. Nat Med. 12, 824-828 (2006).
42. Law, A.J. et al. Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5′ SNPs associated with the disease. Proc. Natl. Acad. Sci. USA 103, 6747-6752 (2006).
43. Carlsson, A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 39 Suppl 1, S10-S14 (2006).
44. Weinberger, D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 44, 660-669 (1987).
45. Davis, K.L., Kahn, R.S., Ko, G. & Davidson, M. Dopamine in schizophrenia: A review and reconceptualization. Am. J. Psychiatry 148, 1474-1486 (1991).
46. Brozoski, T.J., Brown, R.M., Rosvold, H.E. & Goldman, P.S. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkeys. Science 205, 929-932 (1979).
47. Sawaguchi, T. & Goldman-Rakic, P.S. D1 dopamine receptors in prefrontal cortex: Involvement in working memory. Science 251, 947-950 (1991).
48. Sawaguchi, T. & Goldman-Rakic, P.S. The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J. Neurophysiol. 71, 515-528 (1994).
49. Goldman-Rakic, P.S., Lidow, M.S. & Gallagher, D.W. Overlap of dopaminergic, adrenergic, and serotoninergic receptors and complementarity of their subtypes in primate prefrontal cortex. J. Neurosci. 10, 2125-2138 (1990).
50. González-Burgos, G. et al. Dopamine modulation of neuronal function in the monkey prefrontal cortex. Physiol. Behav. 77, 537-543 (2002).
51. Williams, G.V. & Goldman-Rakic, P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376, 572-575 (1995).
52. Sawaguchi, T. The effects of dopamine and its antagonists on directional delay-period activity of prefrontal neurons in monkeys during an oculomotor delayed-response task. Neurosci. Res. 41, 115-128 (2001).
53. Akil, M. et al. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am. J. Psychiatry 156, 1580-1589 (1999).
54. Abi-Dargham, A. et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J. Neurosci. 22, 3708-3719 (2002).
55. Okubo, Y. et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385, 634-636 (1997).
56. Abi-Dargham, A. & Moore, H. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 9, 404-416 (2003).
57. Lewis, D.A. et al. Dopamine transporter immunoreactivity in monkey cerebral cortex: Regional, laminar and ultrastructural localization. J. Comp. Neurol. 432, 119-138 (2001).
58. Tunbridge, E.M., Bannerman, D.M., Sharp, T. & Harrison, P.J. Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J. Neurosci. 24, 5331-5335 (2004).
59. Chen, J. et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 75, 807-821 (2004).
60. Egan, M.F. et al. Effect of COMT Val 108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. USA 98, 6917-6922 (2001).
61. Meyer-Lindenberg, A. et al. Impact of complex genetic variation in COMT on human brain function. Mol. Psychiatry advance online publication 20 June 2006 (doi:10.1038/sj.mp.4001860).
62. Sesack, S.R. & Carr, D.B. Selective prefrontal cortex inputs to dopamine cells: implications for schizophrenia. Physiol. Behav. 77, 513-517 (2002).
63. Kellendonk, C. et al. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 49, 603-615 (2006).
64. Laruelle, M. Dopamine transmission in the schizophrenic brain. in Schizophrenia (eds. Hirsch, S.R. & Weinberger, D.) 365-386 (Blackwell Publishing Co., Malden, Massachusetts, 2003).
65. Rao, S.G., Williams, G.V. & Goldman-Rakic, P.S. Destruction and creation of spatial tuning by disinhibition: GABAA blockade of prefrontal cortical neurons engaged by working memory. J. Neurosci. 20, 485-494 (2000).
66. Sawaguchi, T., Matsumura, M. & Kubota, K. Delayed response deficits produced by local injection of bicuculline into the dorsolateral prefrontal cortex in Japanese macaque monkeys. Exp. Brain Res. 75, 457-469 (1989).
67. Akbarian, S. et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry 52, 258-266 (1995).
68. Volk, D.W., Austin, M.C., Pierri, J.N., Sampson, A.R. & Lewis, D.A. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch. Gen. Psychiatry 57, 237-245 (2000).
69. Volk, D., Austin, M.C., Pierri, J.N., Sampson, A.R. & Lewis, D.A. GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: Decreased expression in a subset of neurons. Am. J. Psychiatry 158, 256-265 (2001).
70. Hashimoto, T. et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J. Neurosci. 23, 6315-6326 (2003).
71. Woo, T-U., Whitehead, R.E., Melchitzky, D.S. & Lewis, D.A. A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc. Natl. Acad. Sci. USA 95, 5341-5346 (1998).
72. Volk, D.W. et al. Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb. Cortex 12, 1063-1070 (2002).
73. Whittington, M.A. & Traub, R.D. Interneuron diversity series: inhibitory interneurons and network oscillations in vitro. Trends Neurosci. 26, 676-682 (2003).
74. Howard, M.W. et al. Gamma oscillations correlate with working memory load in humans. Cereb. Cortex 13, 1369-1374 (2003).
75. Cho, R.Y., Konecky, R.O. & Carter, C.S. Impairments in gamma band synchronization and context processing in schizophrenia. Schizophr. Bull. 31, 450-451 (2005).
76. Akbarian, S. & Huang, H.S. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Res. Brain Res. Rev. published online 8 June 2006 (doi:10.1016/j.brainresrev.2006. 04.001).
77. Spencer, K.M. et al. Neural synchrony indexes disordered perception and cognition in schizophrenia. Proc. Natl. Acad. Sci. USA 101, 17288-17293 (2004).
78. Goldman-Rakic, P.S., Castner, S.A., Svensson, T.H., Siever, L.J. & Williams, G.V. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl.) 174, 3-16 (2004).
79. Coyle, J.T. & Tsai, G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl.) 174, 32-38 (2004).
80. Lewis, D.A., Volk, D.W. & Hashimoto, T. Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: A novel target for the treatment of working memory dysfunction. Psychopharmacology (Berl.) 174, 143-150 (2004).
81. Torrey, E.F. et al. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol. Psychiatry 57, 252-260 (2005).
82. Jones, E.G. Cortical development and thalamic pathology in schizophrenia. Schizophr. Bull. 23, 483-501 (1997).
83. Lewis, D.A. & Moghaddam, B. Cognitive dysfuntion in schizophrenia: convergence of GABA and glutamate alterations. Arch. Neurol. (in the press).
84. Gulyás, A.I., Megías, M., Emri, Z. & Freund, T.F. Total number and ratio of excitatory and inhibitory synapses converging onto single interneurons of different types in the CA1 area of the rat hippocampus. J. Neurosci. 19, 10082-10097 (1999).
85. Melchitzky, D.S. & Lewis, D.A. Pyramidal neuron local axon terminals in monkey prefrontal cortex: Differential targeting of subclasses of GABA neurons. Cereb. Cortex 13, 452-460 (2003).
86. Huntley, G.W. et al. Distribution and synaptic localization of immunocytochemically identified NMDA receptor subunit proteins in sensory-motor and visual cortices of monkey and human. J. Neurosci. 14, 3603-3619 (1994).
87. Huntley, G.W., Vickers, J.C. & Morrison, J.H. Quantitative localization of NMDAR1 receptor subunit immunoreactivity in inferotemporal and prefrontal association cortices of monkey and human. Brain Res. 749, 245-262 (1997).
88. Keilhoff, G., Becker, A., Grecksch, G., Wolf, G. & Bernstein, H.G. Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia. Neuroscience 126, 591-598 (2004).
89. Cochran, S.M. et al. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28, 265-275 (2003).
90. Kinney, J.W. et al. A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J. Neurosci. 26, 1604-1615 (2006).
91. Cunningham, M.O. et al. Region-specific reduction in entorhinal gamma oscillations and parvalbumin-immunoreactive neurons in animal models of psychiatric illness. J. Neurosci. 26, 2767-2776 (2006).
92. Woo, T.-U., Walsh, J.P. & Benes, F.M. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch. Gen. Psychiatry 61, 649-657 (2004).
93. Corfas, G., Roy, K. & Buxbaum, J.D. Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat. Neurosci. 7, 575-580 (2004).
94. Flames, N. et al. Short- and long-range attraction of cortical GABAergic interneurons by neuregulin-1. Neuron 44, 251-261 (2004).
95. Yau, H.J., Wang, H.F., Lai, C. & Liu, F.C. Neural development of the neuregulin receptor ErbB4 in the cerebral cortex and the hippocampus: preferential expression by interneurons tangentially migrating from the ganglionic eminences. Cereb. Cortex 13, 252-264 (2003).
96. Tsukada, H. et al. Chronic NMDA antagonism impairs working memory, decreases extracellular dopamine, and increases D1 receptor binding in prefrontal cortex of conscious monkeys. Neuropsychopharmacology 30, 1861-1869 (2005).
97. Narendran, R. et al. Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am. J. Psychiatry 162, 2352-2359 (2005).
98. Sesack, S.R., Hawrylak, V.A., Melchitzky, D.S. & Lewis, D.A. Dopamine innervation of a subclass of local circuit neurons in monkey prefrontal cortex: Ultrastructural analysis of tyrosine hydroxylase and parvalbumin immunoreactive structures. Cereb. Cortex 8, 614-622 (1998).
99. 1 receptor in interneurons of macaque prefrontal cortex: Distribution and subcellular location. J. Neurosci. 18, 10553-10565 (1998).
100. Zaitsev, A.V. et al. Localization of calcium-binding proteins in physiologically and morphologically characterized interneurons of monkey dorsolateral prefrontal cortex. Cereb. Cortex 15, 1178-1186 (2005).
101. Kroner, S., Krimer, L.S., Lewis, D.A. & Barrionuevo, G. Dopamine increases inhibition in the monkey dorsolateral prefrontal cortex through cell type-specific modulation of interneurons. Cereb. Cortex (doi:10.1093/cercor/ bhl012).
102. Gonzalez-Burgos, G., Kroener, S., Seamans, J.K., Lewis, D.A. & Barrionuevo, G. Dopaminergic modulation of short-term synaptic plasticity in fast-spiking interneurons of primate dorsolateral prefrontal cortex. J. Neurophysiol. 94, 4168-4177 (2005).
103. Mann, E.O., Radcliffe, C.A. & Paulsen, O. Hippocampal gamma-frequency oscillations: from interneurones to pyramidal cells, and back. J. Physiol. (Lond.) 562, 55-63 (2005).
104. Addington, A.M. et al. GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD(67)), is associated with childhood-onset schizophrenia and cortical gray matter volume loss. Mol. Psychiatry 10, 581-588 (2005).
105. Weickert, C.S. et al. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch. Gen. Psychiatry 61, 544-555 (2004).
106. Straub, R.E. et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am. J. Hum. Genet. 71, 337-348 (2002).
107. Millar, J.K. et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 310, 1187-1191 (2005).